About
First Name:
Last Name:
Title and Organization:
Bio:
Dipal Doshi serves as the Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Since becoming the first full-time Entradan in 2017, Dipal has built and led a diverse, scientifically curious and rigorous team focused on developing a new class of intracellular therapies (called Endosomal Escape Vehicle or EEV-therapeutics). Entrada’s goal is to advance its pipeline of EEV therapeutics with the hope of changing the way incurable diseases are treated, transforming the lives of patients and their families.
With more than 20 years of experience in the life science industry, Dipal has led business development, corporate strategy, new product planning and commercial planning for biotechnology and pharmaceutical companies. Prior to Entrada, Dipal served as the Chief Business Officer at Amicus Therapeutics (NASDAQ: FOLD) and held senior-level positions at a healthcare private equity fund and Catalent.
With a passion for patient-focused drug development, Dipal believes that understanding the patient experience and perspective is critical to advancing impactful therapies. That’s why he and the Entrada team proudly partner with patient advocacy organizations to listen and learn from patients and ensure Entrada’s programs are informed by diverse community perspectives.
Dipal received his MBA from The Wharton School of the University of Pennsylvania and his BA from Rutgers University. Dipal serves on the Board of Directors of Azenta Life Sciences (NASDAQ: AZTA), a leading provider of life sciences solutions and āshibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston.
Fellowship Program
Class
